08:00 , Jan 20, 2014 |  BC Week In Review  |  Company News

Axxam, Hit Discovery Constance, Lead Discovery Center, Centre for Drug Design and Discovery (CD3) supply/service, high throughput screening news

CRO Axxam, biotech Lead Discovery and the technology transfer platform and investment fund CD3 debuted their JV, Hit Discovery Constance GmbH, to provide drug discovery research services, including assay development and high throughput screening. The...
07:00 , Sep 6, 2010 |  BC Week In Review  |  Company News

BTG, Nycomed sales and marketing update

BTG said it will accelerate the reacquisition of U.S. marketing rights from Nycomed to CroFab, a polyclonal antibody against rattlesnake venom, and DigiFab, a polyclonal antibody against digoxin (digitalis) glycosides. BTG will...
07:00 , Apr 12, 2010 |  BioCentury  |  Regulation

Forest Runs into Tree

The presentation Forest Laboratories Inc. made at last week's Pulmonary-Allergy Drugs Advisory Committee about Daxas roflumilast to treat COPD would have been perfect - if it had been made a decade ago. For better or...
08:00 , Nov 23, 2009 |  BioCentury  |  Product Development

Nycomed Holding its Breath

Following the May expiry of European patents protecting its biggest-selling drug, Nycomed is hoping COPD compound Daxas roflumilast will help fill part of the revenue gap. If approved, the nonsteroidal phosphodiesterase-4 inhibitor would be the...
08:00 , Nov 16, 2009 |  BC Week In Review  |  Clinical News

Daxas roflumilast: Additional Phase III data

Additional data from the double-blind, international Phase III AURA trial in 1,523 patients showed that that once-daily 500 ug oral Daxas for 52 weeks significantly improved mean pre-bronchodilator FEV1 by 39 mL vs. placebo (46...
08:00 , Nov 16, 2009 |  BC Week In Review  |  Clinical News

Daxas roflumilast: Additional Phase III data

Additional data from the double-blind, international Phase III EOS trial in 933 patients showed that once-daily 500 ug oral Daxas plus Serevent salmeterol for 24 weeks significantly improved mean pre- and post-bronchodilator FEV1 by...
08:00 , Nov 16, 2009 |  BC Week In Review  |  Clinical News

Daxas roflumilast: Additional Phase III data

Additional data from the double-blind, international Phase III HERMES trial in 1,568 patients showed that that once-daily 500 ug oral Daxas for 52 weeks significantly improved mean pre-bronchodilator FEV1 by 58 mL vs. placebo (33...
08:00 , Nov 16, 2009 |  BC Week In Review  |  Clinical News

Daxas roflumilast: Additional Phase III data

Additional data from the double-blind, international Phase III HELIOS trial in 743 patients showed that once-daily 500 ug oral Daxas plus Spiriva tiotropium for 24 weeks significantly improved breathlessness as measured by a reduction...
07:00 , Sep 7, 2009 |  BC Week In Review  |  Clinical News

Daxas roflumilast: Additional Phase III data

Additional data from 2 double-blind, international Phase III trials (HERMES and AURA) showed that Daxas significantly improved mean pre-bronchodilator FEV1 by 48 mL vs. placebo (p<0.0001) and significantly reduced the rate of exacerbations that were...
07:00 , Sep 7, 2009 |  BC Week In Review  |  Clinical News

Daxas roflumilast: Additional Phase III data

Additional data from 2 double-blind, international Phase III trials (EOS and HELIOS) showed that Daxas significantly improved mean pre-bronchodilator FEV1 by 49 mL in patients treated with Serevent salmeterol vs. placebo (p<0.0001) and by...